Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not disclosedLoading investors…
Activity from announced rounds
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
Develops first-in-class small molecule therapies for neurodegenerative disease via glial cell signaling platform